2-iodo-arabinoadenosine | 252552-32-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-iodo-arabinoadenosine
• 英文别名: (2R,3S,4S,5R)-2-(6-amino-2-iodopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 252552-32-2
• 化学式: C₁₀H₁₂IN₅O₄
• 分子量: 393.141
• InChiKey: MGEBVSZZNFOIRB-FJFJXFQQSA-N

物化性质

• 沸点：
  776.3±70.0 °C(Predicted)
• 密度：
  2.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-iodo-arabinoadenosine 、 (1,12-dicarba-closo-dodecaboran-2-yl)ethyne 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.42h， 以79%的产率得到2-ethynyl-(1,12-dicarba-closo-dodecaboran-2-yl)arabinoadenosine
  参考文献：
  名称：

  [EN] A NUCLEOSIDE DERIVATIVE CONTAINING A BORON CLUSTER FOR USE AS A DRUG, PARTICULARLY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
  [FR] DÉRIVÉ DE NUCLÉOSIDE DESTINÉ À ÊTRE UTILISÉ EN TANT QUE MÉDICAMENT, EN PARTICULIER POUR LE TRAITEMENT DE LA LEUCÉMIE LYMPHOCYTAIRE CHRONIQUE

  摘要：

  公开号：

  WO2016020858A3

文献信息

• METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF
  申请人：Barre Louisa

  公开号：US20100290990A1

  公开（公告）日：2010-11-18

  The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18 F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18 F which can be obtained by or during a method according to the invention and its various uses.

  本发明涉及一种制备用放射性同位素18F标记的2-氟嘌呤的方法，包括对2-硝基嘌呤衍生物进行氟化步骤。本发明包括一种用放射性同位素18F标记的2-氟嘌呤衍生物，可以通过本发明的方法获得，以及其各种用途。
• Novel arabinosyladenine derivatives
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0967220A1

  公开（公告）日：1999-12-29

  [Objects] An object of the present invention is to offer an Ara-A derivative having a resistance to the metabolism by ADA and also having a sufficient antiviral action. [Constitution] A novel 2-substituted arabinosyladenine derivative represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof. [In the formula, Z is alkyl having more than 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl.] [Merit] The compounds of the present invention are Ara-A derivatives having a resistance to the metabolism by ADA and having a sufficient antiviral action whereby the problems in the prior art have been solved. The compounds of the present invention are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show a good behavior in blood with an excellent sustaining property but also are capable of being orally administered whereby their usefulness is very high.

  目的 本发明的目的是提供一种 Ara-A 衍生物，该衍生物具有抗 ADA 代谢的能力，并具有足够的抗病毒作用。 构成 一种由式(I)代表的新型 2-取代的阿拉伯核糖基腺嘌呤衍生物及其药学上可接受的盐和水合物。 [式中，Z 为具有 4 个以上碳原子的烷基、烯基或炔基，R 为氢或低级烷基。］ 优点 本发明的化合物是 Ara-A 衍生物，具有抗 ADA 代谢的能力和足够的抗病毒作用，从而解决了现有技术中存在的问题。本发明的化合物可作为治疗或预防 DNA 病毒感染疾病的药物，如单纯疱疹病毒（HSV）、带状疱疹病毒、巨细胞病毒（CMV）、腺病毒、肝炎病毒或疫苗病毒。与 Ara-A 相比，它们不仅在血液中表现良好，具有出色的持续性，而且能够口服给药，因此具有很高的实用性。
• In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification
  作者：Jolanta D. Żołnierczyk、Agnieszka B. Olejniczak、Adam Mieczkowski、Jerzy Z. Błoński、Zofia M. Kiliańska、Tadeusz Robak、Zbigniew J. Leśnikowski

  DOI：10.1016/j.bmc.2016.08.028

  日期：2016.11

  A series of adenosine derivatives bearing a boron cluster were synthesized and evaluated for their cytotoxicity against primary peripheral mononuclear cells from the blood of 17 patients with leukemias (16 CLL and 1 very rare PLL), as well as from 5 healthy donors used as a control. Among the tested agents, two, i.e., compounds 1 and 2, displayed high in vitro cytotoxicity and proapoptotic potential on leukemic cells, with only scarce activity being seen against control cells. Biological tests related to apoptosis revealed the activation of the main execution apoptotic enzyme, procaspase-3, in CLL and PLL cells exposed to compounds 1 and 2. Moreover, the above compounds indicated high activity in the proteolysis of the apoptotic markers PARP-1 and lamin B1, fragmentation of DNA, and the induction of some changes in the expression of the Mcl-1, protein apoptosis regulator in comparison with control cells. (C) 2016 Elsevier Ltd. All rights reserved.
• A Nucleoside Derivative For Use As A Drug, Particularly For The Treatment Of Chronic Lymphocytic Leukemia
  申请人：INSTYTUT BIOLOGII MEDYCZNEJ POLSKIEJ AKADEMII NAUK

  公开号：US20170216340A1

  公开（公告）日：2017-08-03

  We disclose nucleoside derivatives useful as drugs, particularly for the treatment of chronic lymphocytic leukemia.
• US6242429B1
  申请人：——

  公开号：US6242429B1

  公开（公告）日：2001-06-05